• Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, Pontari MA, McNaughton-Collins M., Shoskes DA, Comiter CV, Datta NS, Fowler JE Jr, Nadler RB, Zeitlin SI, Knauss JS, Wang Y., Kusek JW, Nyberg LM Jr, Litwin MS, Chronic Prostatitis Collaborative Research Network, Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: A randomized, double-blind trial. Ann Intern Med. 2004;141: 581589.
  • Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T., Yang JR, Yap HW, Krieger JN. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol. 2003;169: 592596.
  • Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60: 7883.
  • El-Hakim A.. Chronic prostatitis/chronic pelvic pain syndrome: is there a role for local drug infiltration therapy? J Endourol. 2004;18: 227231.
  • Evliyaoglu Y., Burgut R.. Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo. Int Urol Nephrol. 2002;34: 351356.
  • Gul O., Eroglu M., Ozok U.. Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol. 2001;32: 433436.
  • Hua VN, Schaeffer AJ. Acute and chronic prostatitis. Med Clin N Am. 2004;88: 483494.
  • Krieger JN. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol Nefrol. 2004;56: 99107.
  • Krieger JN, Nyberg L. Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA (J Am Med Assoc). 1999;282: 236237.
  • Lowe FC. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004;26: 17011713.
  • Lu M., Zhao ST, Wang SM, Shi BK, Fan YD, Wang JZ. [Alphα-blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH-IIIa): a prospective, placebo-controlled trial]. Zhonghua Liuxing Bingxue Zazhi. 2004;25: 169172.
  • McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, et al. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349: 23872398.
  • McNaughton Collins M, MacDonald R., Wilt TJ. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med. 2000;133: 367381.
  • Mehik A., Alas P., Nickel JC, Sarpola A., Helstrom PJ. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology. 2003;62: 425429.
  • Moher D., Jadad AR, Tugwell P.. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care. 1996;12: 195208.
  • Nickel JC, Narayan P., McKay J., Doyle C.. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol. 2004;171: 15941597.
  • Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment. Drugs Aging. 2003;20: 11111125.
  • Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology. 2004;63(suppl 1): 7584.
  • Shen B., Jin X., Cai S., Chen J., Chen G., Zhao W., Sun X.. [Effect and mechanism of alpha1-adrenoceptor blocker combined with antibiotics for chronic prostatitis]. Zhonghua Nan Ke Xue. 2004;10: 518520.
  • Turner JA, Ciol MA, Von Korff M., Rothman I., Berger RE. Healthcare use and costs of primary and secondary care patients with prostatitis. Urology. 2004;63: 10311035.
  • Wang J., Li J., Lu R., Wang JM. [Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis]. Zhonghua Nan Ke Xue. 2002;8: 4850.